IRIS Accounts Production v24.3.2.46 09078567 director 1.7.23 30.6.24 30.6.24 false true false false true false iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh090785672023-06-30090785672024-06-30090785672023-07-012024-06-30090785672022-06-30090785672022-07-012023-06-30090785672023-06-3009078567ns15:EnglandWales2023-07-012024-06-3009078567ns14:PoundSterling2023-07-012024-06-3009078567ns10:Director12023-07-012024-06-3009078567ns10:PrivateLimitedCompanyLtd2023-07-012024-06-3009078567ns10:SmallEntities2023-07-012024-06-3009078567ns10:AuditExemptWithAccountantsReport2023-07-012024-06-3009078567ns10:SmallCompaniesRegimeForDirectorsReport2023-07-012024-06-3009078567ns10:SmallCompaniesRegimeForAccounts2023-07-012024-06-3009078567ns10:FullAccounts2023-07-012024-06-3009078567ns10:CompanySecretary12023-07-012024-06-3009078567ns10:RegisteredOffice2023-07-012024-06-3009078567ns5:CurrentFinancialInstruments2024-06-3009078567ns5:CurrentFinancialInstruments2023-06-3009078567ns5:ShareCapital2024-06-3009078567ns5:ShareCapital2023-06-3009078567ns5:RetainedEarningsAccumulatedLosses2024-06-3009078567ns5:RetainedEarningsAccumulatedLosses2023-06-3009078567ns5:PlantMachinery2023-07-012024-06-3009078567ns5:FurnitureFittings2023-07-012024-06-3009078567ns5:ComputerEquipment2023-07-012024-06-3009078567ns5:PlantMachinery2023-06-3009078567ns5:FurnitureFittings2023-06-3009078567ns5:ComputerEquipment2023-06-3009078567ns5:PlantMachinery2024-06-3009078567ns5:FurnitureFittings2024-06-3009078567ns5:ComputerEquipment2024-06-3009078567ns5:PlantMachinery2023-06-3009078567ns5:FurnitureFittings2023-06-3009078567ns5:ComputerEquipment2023-06-3009078567ns5:CurrentFinancialInstrumentsns5:WithinOneYear2024-06-3009078567ns5:CurrentFinancialInstrumentsns5:WithinOneYear2023-06-30090785671ns10:Director12023-06-30090785671ns10:Director12022-06-30090785671ns10:Director12023-07-012024-06-30090785671ns10:Director12022-07-012023-06-30090785671ns10:Director12024-06-30090785671ns10:Director12023-06-30
REGISTERED NUMBER: 09078567 (England and Wales)















Unaudited Financial Statements for the Year Ended 30 June 2024

for

Harvey Pharma Ltd

Harvey Pharma Ltd (Registered number: 09078567)

Contents of the Financial Statements
for the Year Ended 30 June 2024










Page

Company Information 1

Chartered Accountants' Report 2

Balance Sheet 3

Notes to the Financial Statements 5


Harvey Pharma Ltd

Company Information
for the Year Ended 30 June 2024







DIRECTOR: Mr Jeremiah Nguru Kiiru



SECRETARY: Mrs Mercy Wambui Nguru



REGISTERED OFFICE: Unit 6
Carbrook Business Park
Dunlop Street
Sheffield
South Yorkshire
S9 2HR



REGISTERED NUMBER: 09078567 (England and Wales)



ACCOUNTANTS: Landin Wilcock & Co
Chartered Accountants
68 Queen Street
Sheffield
South Yorkshire
S1 1WR



BANKERS: Barclays Bank
Sheffield City
Leicester
Leicestershire
LE87 2BB

Chartered Accountants' Report to the Director
on the Unaudited Financial Statements of
Harvey Pharma Ltd


The following reproduces the text of the report prepared for the director in respect of the company's annual unaudited financial statements. In accordance with the Companies Act 2006, the company is only required to file a Balance Sheet. Readers are cautioned that the Income Statement and certain other primary statements and the Director's Report are not required to be filed with the Registrar of Companies.

In order to assist you to fulfil your duties under the Companies Act 2006, we have prepared for your approval the financial statements of Harvey Pharma Ltd for the year ended 30 June 2024 which comprise the Income Statement, Other Comprehensive Income, Balance Sheet, Statement of Changes in Equity and the related notes from the company's accounting records and from information and explanations you have given us.

As a practising member firm of the Institute of Chartered Accountants in England and Wales (ICAEW), we are subject to its ethical and other professional requirements which are detailed within the ICAEW's regulations and guidance at http://www.icaew.com/en/membership/regulations-standards-and-guidance.

This report is made solely to the director of Harvey Pharma Ltd in accordance with our terms of engagement. Our work has been undertaken solely to prepare for your approval the financial statements of Harvey Pharma Ltd and state those matters that we have agreed to state to the director of Harvey Pharma Ltd in this report in accordance with ICAEW Technical Release 07/16AAF. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than Harvey Pharma Ltd and its director for our work or for this report.

It is your duty to ensure that Harvey Pharma Ltd has kept adequate accounting records and to prepare statutory financial statements that give a true and fair view of the assets, liabilities, financial position and profit of Harvey Pharma Ltd. You consider that Harvey Pharma Ltd is exempt from the statutory audit requirement for the year.

We have not been instructed to carry out an audit or a review of the financial statements of Harvey Pharma Ltd. For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the statutory financial statements.






Landin Wilcock & Co
Chartered Accountants
68 Queen Street
Sheffield
South Yorkshire
S1 1WR


14 January 2025

Harvey Pharma Ltd (Registered number: 09078567)

Balance Sheet
30 June 2024

30/6/24 30/6/23
Notes £    £   
FIXED ASSETS
Tangible assets 4 12,913 12,271

CURRENT ASSETS
Stocks 45,820 31,565
Debtors 5 1,498,103 1,353,001
Investments 6 1,024,224 -
Cash at bank and in hand 1,444,408 2,106,506
4,012,555 3,491,072
CREDITORS
Amounts falling due within one year 7 (606,009 ) (543,761 )
NET CURRENT ASSETS 3,406,546 2,947,311
TOTAL ASSETS LESS CURRENT LIABILITIES 3,419,459 2,959,582

PROVISIONS FOR LIABILITIES (3,014 ) (3,067 )
NET ASSETS 3,416,445 2,956,515

CAPITAL AND RESERVES
Called up share capital 100 100
Retained earnings 3,416,345 2,956,415
3,416,445 2,956,515

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 30 June 2024.

The members have not required the company to obtain an audit of its financial statements for the year ended 30 June 2024 in accordance with Section 476 of the Companies Act 2006.

The director acknowledges his responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

Harvey Pharma Ltd (Registered number: 09078567)

Balance Sheet - continued
30 June 2024


The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the director and authorised for issue on 14 January 2025 and were signed by:





Mr Jeremiah Nguru Kiiru - Director


Harvey Pharma Ltd (Registered number: 09078567)

Notes to the Financial Statements
for the Year Ended 30 June 2024


1. STATUTORY INFORMATION

Harvey Pharma Ltd is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

The presentation currency of the financial statements is the Pound Sterling (£).


2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Turnover
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off the cost less estimated residual value of each asset over its estimated useful life.
Plant and machinery - 20% on reducing balance
Fixtures and fittings - 20% on reducing balance
Computer equipment - 33% on cost

Tangible fixed assets are initially measured at cost. Subsequently, they are measured at cost less accumulated depreciation and impairment losses.

Stocks
Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.

Financial instruments
Financial assets and financial liabilities are recognised when the company becomes party to the contractual provisions of the instrument. Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the asset of the company after deducting all of its liabilities.

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.


Harvey Pharma Ltd (Registered number: 09078567)

Notes to the Financial Statements - continued
for the Year Ended 30 June 2024


2. ACCOUNTING POLICIES - continued
Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Foreign currencies
Assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the rate of exchange ruling at the date of transaction. Exchange differences are taken into account in arriving at the operating result.

Pension costs and other post-retirement benefits
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

Going concern
The director considers the company to be a going concern.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 6 (2023 - 5 ) .

4. TANGIBLE FIXED ASSETS
Fixtures
Plant and and Computer
machinery fittings equipment Totals
£    £    £    £   
COST
At 1 July 2023 2,500 21,748 15,305 39,553
Additions - 895 3,975 4,870
At 30 June 2024 2,500 22,643 19,280 44,423
DEPRECIATION
At 1 July 2023 733 14,617 11,932 27,282
Charge for year 354 1,536 2,338 4,228
At 30 June 2024 1,087 16,153 14,270 31,510
NET BOOK VALUE
At 30 June 2024 1,413 6,490 5,010 12,913
At 30 June 2023 1,767 7,131 3,373 12,271

Harvey Pharma Ltd (Registered number: 09078567)

Notes to the Financial Statements - continued
for the Year Ended 30 June 2024


5. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
30/6/24 30/6/23
£    £   
Trade debtors 1,437,286 1,296,801
Other debtors 60,817 56,200
1,498,103 1,353,001

6. CURRENT ASSET INVESTMENTS
30/6/24 30/6/23
£    £   
Other 1,024,224 -

7. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
30/6/24 30/6/23
£    £   
Trade creditors 362,725 369,700
Taxation and social security 220,001 138,940
Other creditors 23,283 35,121
606,009 543,761

8. DIRECTOR'S ADVANCES, CREDITS AND GUARANTEES

The following advances and credits to a director subsisted during the years ended 30 June 2024 and 30 June 2023:

30/6/24 30/6/23
£    £   
Mr Jeremiah Nguru Kiiru
Balance outstanding at start of year (18,477 ) 1,523
Amounts advanced 220,000 180,000
Amounts repaid (200,000 ) (200,000 )
Amounts written off - -
Amounts waived - -
Balance outstanding at end of year 1,523 (18,477 )